Effect of chronic bromocriptine treatment on psychological profile of patients with PRL-secreting pituitary adenomas.
Hyperprolactinaemic patients are characterized by an altered psychological profile, positively modified by the administration of dopaminergic drugs. This would suggest that the same neurochemical disorder is responsible for both hyperprolactinaemia and abnormal psychological profile in these patients. To identify depression, anxiety, and aggressiveness, nine women affected by prolactin (PRL)-secreting pituitary adenomas were studied before and after 6 and 12 mo of bromocriptine therapy, by the use of different psychometric tests (Mean Minnesota Multiphasic Personality Inventory [MMPI], State-Trait Anxiety Inventory [STAI], and State and Trait Aggressiveness Scale [STAS]). As a group, the patients did not show any depressive, anxious, or aggressive tendencies. Furthermore, no significant modifications were observed during dopaminergic treatment. Patients bearing PRL adenomas seem to be characterized by a dopaminergic background different from that found in functional hyperprolactinaemia. This hypothesis could explain the different psychological configuration and behavior in response to the administration of dopaminergic compounds.
Rocco
A
A
Fifth Medical Clinic, University of Rome La Sapienza, Italy.
Mori
F
F
Baldelli
R
R
Aversa
A
A
Munizzi
M R
MR
Nardone
M R
MR
Fabbrini
A
A
Falaschi
P
P
D000328:Adult; D000374:Aggression; D001007:Anxiety / Q000523:psychology; D001971:Bromocriptine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006728:Hormones / Q000097:blood; D006791:Hostility; D006801:Humans; D008950:MMPI; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000523:psychology*; D015175:Prolactinoma / Q000188:drug therapy / Q000378:metabolism / Q000523:psychology*; D011581:Psychological Tests
D006728:Hormones; D001971:Bromocriptine